Description
Pazopanib 200 mg and 400 mg strength
Crucial in treating advanced kidney cancer and soft tissue sarcoma, Pazopanib slows tumor growth. Its strengths offer flexibility in dosing and treatment effectiveness.
Pazopanib Generic manufacturer in India
- Natco Pazopanib 400 mg – Pazonat.
- Hetero Pazopanib 400 mg – Pazinib.
- Cipla Pazopanib 400 mg – Pazoci.
- Cipla Pazopanib 400 mg – Pazoci.
Pazopanib Price in India:
- Pazopanib Price in India
- INR 200 mg – ₹2133
- INR 400 mg – ₹3684
Please note: These prices vary depending on the brand and pharmacy chosen.
Pazopanib Mechanism of Action
Pazopanib blocks specific proteins that help cancer cells grow and spread. It particularly cuts off the blood supply that tumors need to grow.
This mechanism makes it effective for treating certain cancers like advanced kidney and soft tissue cancers. Here, take a glance at how it helps in treatment of these cancers –
For renal cell carcinoma
Pazopanib blocks blood vessel growth in tumors, starving them of nutrients and thereby shrinking them.
For breast cancer
Pazopanib inhibits proteins that promote cancer cell growth and blood vessel formation.
Pazopanib Side Effects
- Nausea/vomiting
- Fatigue
- Loss of appetite
- Altered sense of taste
- Numbness/tingling/redness in hands/feet, or feeling tired/weak
- Temporary hair loss and changes in hair or skin color
- Serious side effects include:
- Swollen ankles/feet, unusual tiredness (Heart failure symptoms)
- Unusual weight gain, cold intolerance, slow heartbeat
- Sore throat, fever, chills, cough
- Wounds that don’t heal
Immediately consult your doctor for any serious side effects. Also, ensure regular medical monitoring
Comparison of Pazopanib, Sunitinib, Cabozantinib, and Sorafenib
Features | Pazopanib | Sunitinib | Cabozantinib | Sorafenib |
---|---|---|---|---|
Treatment | Kidney & soft tissue cancer | Kidney & gastrointestinal cancer | Kidney, liver, & thyroid cancer | Kidney, liver, & thyroid cancer |
Common Side Effects | Liver issues, nausea, fatigue | Fatigue, mouth sores, high BP | Diarrhea, nausea, hand-foot syndrome | Rash, diarrhea, fatigue |
Effectiveness | Slows cancer growth; manageable side effects | Effective but with more side effects | Effective for advanced cancers | Broadly used, moderate effectiveness |
FAQs
What cancer does Pazopanib treat?
Pazopanib treats cancers such as Advanced kidney and soft tissue sarcomas.
When should I stop taking Pazopanib?
You should stop consuming this medicine as directed by your doctor if side effects or no benefit occur.
What are the benefits of Pazopanib?
The benefits of Pazopanib are that it slows tumor growth and limits cancer spread.
What drugs interact with Pazopanib?
Antacids, pemetrexed, lapatinib, rifampin, and blood thinners are among the drugs that interact with Pazopanib.
What type of drug is Pazopanib?
Pazopanib is a drug – tyrosine kinase inhibitor that targets tumors.
What is the success rate of Pazopanib?
The success rate of Pazopanib varies. It helps extend progression-free survival and overall survival (OS).
References –
https://www.drugs.com/mtm/Pazopanib.html
https://en.wikipedia.org/wiki/Pazopanib
https://medicaldialogues.in/generics/pazopanib-2727251#dosagestrengths
https://www.webmd.com/drugs/2/drug-153214/Pazopanib-oral/details
NOTE:
This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does not include all information about the possible uses, directions, side effects, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This is prescription medicine and if you want to buy this medication legally from Delightaid Health, we require a valid prescription from you. Please consult with your doctor before taking this medicine. Only your doctor can decide which medicine is good for you. Please read the disclaimer and prescription-related full details at the bottom of this website.
Genuine Customer Review
Reviews
There are no reviews yet.